Chest CT (Computed Tomography) has long played a critical role in the early detection of thoracic diseases such as lung cancer, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis. However, with the growing global demand for low-dose CT (LDCT) screening, medical professionals—especially radiologists and pulmonologists—are facing increasing challenges.
A Dutch study showed that between 2008 and 2019, the number of annual chest CT exams in just two hospitals more than doubled—from 10,000 to over 20,000. During the same period, the detection rate for pulmonary nodules rose from 38% to 50%.
While this surge has helped improve early cancer detection, it has also significantly increased the workload of diagnostic specialists. Radiologists now face a dual challenge: repetitive, time-intensive nodule analysis and mounting burnout due to case volume and staffing shortages.
Compounding this issue is the fact that most missed early lung cancers occur at the image interpretation stage. Despite strong clinical recommendations, only 18% of high-risk patients in the U.S. actually undergo LDCT screening (American Cancer Society, 2024).
The takeaway? Clinical workflows urgently require technological support to scale screening efforts and enhance diagnostic accuracy. And that’s exactly where AI steps in—not as a supplementary tool, but as a transformative force.
The American Thoracic Society (ATS) 2025 conference will be held this May in San Francisco, showcasing the latest innovations in pulmonary diagnostics. AI-powered imaging, in particular, will take center stage through several key sessions
Explore the full ATS 2025 program
AI is no longer a theoretical concept. It is now being deployed in hospitals across the globe to assist with high-volume image analysis, reduce interpretation time, and support more accurate clinical decisions.
Coreline Soft’s AVIEW LCS Plus exemplifies this transition from lab to clinic. Designed for real-world workflow integration, the platform delivers:
Coreline Soft participates in ATS 2025 with a portfolio of internationally certified AI solutions—backed by FDA, CE, and HIPAA clearances.
The company’s flagship product, AVIEW LCS Plus, offers a 3-in-1 chest CT-based AI platform capable of simultaneously analyzing lung cancer, cardiovascular disease, and COPD from a single scan.
Already adopted in national screening pilot programs across Europe and Asia, AVIEW LCS Plus integrates AI-powered detection, Lung-RADS classification, follow-up comparison, and malignancy risk estimation into a unified platform—designed for real clinical environments.
AI is revolutionizing thoracic diagnostics, improving diagnosis, expanding access, and increasing clinical confidence. ATS 2025 is your chance to witness this revolution firsthand.
In other words, ATS 2025 is not about when the future of AI chest CT will arrive, but how it is already happening. The clinical and regulatory frameworks are in place and the solutions are ready. AI is improving diagnostic accuracy, easing workload, and enabling scalable early screening globally.
At ATS 2025, Coreline Soft will be showcasing AI imaging technology that you can see, touch, and demo to connect innovation with real-world impact. Let's shape the future of lung screening together.
Register for the ATS 2025 Demo Today
Contact us
General inquiries
Business Department
Overseas Business Department
Customer Service Team
IR-related inquiries
List